Pharma Company Aims for Stock Exchange Rebound

  • Endo Inc. advances plans to list on NYSE
  • Two years after filing for bankruptcy due to opioid litigation and generic competitors
  • Newly formed entity Endo Inc. purchased assets of Endo International PLC in April
  • Endo trades over-the-counter under symbol NDOI
  • Plans to sell 12.6 million shares by current stockholders
  • No shares being sold by the company itself
  • Intends to list on NYSE under symbol NDO
  • Low volume since debuting on OTCQX Best Market in June
  • Shares closed at $28.25 on Thursday
  • Trading on NYSE expected later in 2024, subject to conditions and approvals

Endo Inc., a pharmaceutical company that faced bankruptcy due to opioid litigation and generic competition, has advanced its plans to list on the New York Stock Exchange. After acquiring most of Endo International PLC’s assets in April, it filed a registration statement for potential 12.6 million shares sale by current stockholders. The company does not sell shares itself. It will trade under symbol NDO on NYSE. Shares closed at $28.25 on Thursday, with trading expected later this year, pending conditions and approvals.

Factuality Level: 8
Factuality Justification: The article provides accurate information about Endo Inc.’s plans to list on the New York Stock Exchange and its financial performance without any sensationalism or irrelevant details.
Noise Level: 6
Noise Justification: The article provides relevant information about Endo Inc.’s plans to list on the NYSE and its financial performance, but it lacks in-depth analysis or exploration of the consequences of the company’s decisions and does not offer actionable insights for readers.
Public Companies: Endo Inc. (NDO)
Private Companies: Endo International PLC
Key People: Josh Beckerman (Author)

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: Endo Inc.
Financial Rating Justification: The article discusses the company’s plans to list on the New York Stock Exchange and its impact on Endo Inc.’s stock trading, which is related to financial markets and the company’s financial performance.
Presence Of Extreme Event: b
Nature Of Extreme Event: Financial Crisis (bankruptcy of a major corporation)
Impact Rating Of The Extreme Event: Severe
Extreme Rating Justification: Endo International filed for bankruptcy due to pressure from opioid litigation and generic competitors, causing significant financial impact on the company.

Reported publicly: www.marketwatch.com